<DOC>
	<DOCNO>NCT02734069</DOCNO>
	<brief_summary>This study evaluate association body composition ( mainly free-fat mass ) , clinical biochemical parameter development toxicity patient treatment Carboplatin/Paclitaxel advance NSCLC .</brief_summary>
	<brief_title>Impact Fat-free Mass Carboplatin Calculated Dose Chemotherapeutic Toxicity Patients With Advanced NSCLC</brief_title>
	<detailed_description>BACKGROUND Lung cancer ( LC ) lead cause cancer death worldwide , attribute 13 % new case cancer account 19.4 % deaths malignancy . In Mexico , cancer also lead cause death malignant neoplasia . One reason attributable high mortality disease case detect advanced stage depend prognosis treatment . Within classification LC prevalent Non Small Cell Lung Cancer ( NSCLC ) ; consider first-line standard treatment palliative cytotoxic chemotherapy , combination carboplatin paclitaxel hand one recent combination Carboplatin Pemetrexed . Malnutrition may affect 80 % patient advanced cancer associate 20 % death , increase risk development complication mortality extend hospital stay 90 % , increase cost treatment 35-75 % . Similarly , previous study INCan , degree malnutrition patient LC associate cytotoxic chemotherapy toxicity poor prognosis poorer quality life . Sarcopenia also phenomenon commonly observed patient LC , prevalence 61 % 31 % men woman respectively . Carboplatin dose administer patient calculate Calvert formula , require calculation glomerular filtration rate ( GFR ) . There various quantify estimate method calculate GFR ; however validate commonly use estimate Cockroft-Gault formula . It known due various factor , variable require calculation ( creatinine ) could modify result , may become unreliable , important consider change body composition NSCLC patient sarcopenia . HYPOTHESIS : Sarcopenia participant receive 20 % dose Carboplatin per Free Fat Mass ( kg / mg ) without sarcopenia . Sarcopenic patient , severe toxicity relate chemotherapy without sarcopenia . METHODOLOGY : NSCLC patient advance NSCLC ( inoperable stage III IV ) include . Clinicopathological baseline patient age , sex , stage , ECOG , weight , height , body composition , Subjective Global Assessment , frequency food consumption , albumin , hemoglobin , hematocrit , glomerular filtration rate , carboplatin administer dosage , quality life , etc . A subsequent follow-up evaluation make 1st 2nd cycle treatment assess toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Sarcopenia</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Diagnosis NSCLC Stage IV ( stratification accord American Joint Committee Cancers 7th edition ) Candidates treatment carboplatin plus paclitaxel 1st line Performance status ( ECOG 02 ) Laboratory study demonstrate adequate renal , hepatic hematologic function ( blood chemistry blood count ) Normal renal ultrasound prior initiation treatment Patients renal impairment ( KDOQI 35 ) Patients compute tomography study baseline Uncontrolled blood pressure ( &gt; 140 mmHg ) Uncontrolled diabetes ( &gt; 130 mg / dL ) Obstruction kidney ( ) ureter ( ) Dehydrated patient Patients high consumption NSAIDs ( aspirin , ibuprofen , etc. &gt; 1 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>carboplatin</keyword>
</DOC>